Bortezomib for the treatment of multiple myeloma
is a topic covered in the Evidence-Based Medicine Guidelines
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
"Bortezomib for the Treatment of Multiple Myeloma." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305230/all/Bortezomib_for_the_treatment_of_multiple_myeloma.
Bortezomib for the treatment of multiple myeloma. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305230/all/Bortezomib_for_the_treatment_of_multiple_myeloma. Accessed October 19, 2019.
Bortezomib for the treatment of multiple myeloma. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/1305230/all/Bortezomib_for_the_treatment_of_multiple_myeloma
Bortezomib for the Treatment of Multiple Myeloma [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 October 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305230/all/Bortezomib_for_the_treatment_of_multiple_myeloma.
TY - ELEC
T1 - Bortezomib for the treatment of multiple myeloma
ID - 1305230
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305230/all/Bortezomib_for_the_treatment_of_multiple_myeloma
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine